MyMedR

Benign prostatic hyperplasia: Surgery and alternative surgery

Ng PEP

Family Physician, 1995;7:12-15.

Matched MeSH terms: Prostatic Hyperplasia

Fulltext Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia

Yoong HF, Sundaram MB, Aida Z

Med J Malaysia, 2005 Aug;60(3):294-6.

Nocturia is a common symptom associated with benign prostatic hyperplasia which can persist even after effective treatment of BPH. Other causes may be responsible. We investigated a group of patients who were treated for BPH and continue to have nocturia. Our study has found a high prevalence (85.4%) of nocturnal polyuria in this group of patients. It has important clinical implication since the condition can be effectively treated with oral desmopressin. Empirical treatment without a routine frequency volume chart may be appropriate due to its high prevalence.

Matched MeSH terms: Prostatic Hyperplasia/epidemiology*

Fulltext The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis

Lee SWH, Chan EMC, Lai YK

Sci Rep, 2017 08 11;7(1):7984.

PMID: 28801563 DOI: 10.1038/s41598-017-06628-8

Benign prostatic hyperplasia is a common non-malignant condition among older men, but the epidemiology is poorly characterised. We summarised and determined the global prevalence of benign prostatic hyperplasia. A systematic search on PubMed, EMBASE and CENTRAL was performed up until 31st July 2016. Studies that described the epidemiology of benign prostatic hyperplasia were included and cumulative plots of prevalence estimates were calculated. A total of 31 prevalence rate estimates from 25 countries were identified. The combined prevalence estimates showed that the lifetime prevalence of BPH was 26.2% (95% CI: 22.8-29.6%). We found that there was an increasing prevalence of BPH with age. However, we found no significant difference between (a) rural, urban or mixed sites, (b) different countries, (c) respondent representativeness. (d) sample size or (e) study quality. We also found no significant change in the prevalence over the past 20 years. While there is substantial variation between sites estimates, results suggest that nearly 1 in 4 men will suffer from BPH over their lifetime. The study revealed there are significant gaps in knowledge, which provides opportunities for future research to further enrich the epidemiological landscape with data.

Matched MeSH terms: Prostatic Hyperplasia/epidemiology*

Benign prostatic hyperplasia: Medical therapy

Tan HM, Lei CCM

Family Physician, 1995;7:16-21.

Medical therapy is effective in patients with mild to moderate symptoms of benign prostatic hyperplasia. Selective alpha-1 blockers (e.g. terazosin) and 5 alpha reductase inhibitors (e.g. finasteride) are the main drugs used. Alpha blockers reduce the dynamic component of obstruction while the later reduces the size of the prostate.

Matched MeSH terms: Prostatic Hyperplasia

Fulltext Embozene loaded prostatic artery embolization

Ezamin Abdul Rahim, Ridzuan Abdul Rahim, Azzam Baseri Huddin, Nik Azuan Nik Ismail, Mohd Naim Mohd Yakob

Malaysian Journal of Medicine and Health Sciences, 2020;16(3):313-315.

MyJurnal

Herein is a case report of a 70 years old man with a tenacious benign prostatic hyperplasia (BPH). The aim of this manuscript is to briefly discuss the usage and advantage of EmbozeneTM Microsphere in embolization of the pros- tate arteries in the treatment of failed medical and surgical therapy for BPH.

Matched MeSH terms: Prostatic Hyperplasia

Benign prostatic hyperplasia: Clinical features

Yap HW

Family Physician, 1995;7:9-11.

Matched MeSH terms: Prostatic Hyperplasia

Benign prostatic hyperplasia: Investigations

Lim CS

Family Physician, 1995;7:6-8.

Matched MeSH terms: Prostatic Hyperplasia

Benign prostatic hyperplasia: Epidemiology and pathogenesis

Lei CCM

Family Physician, 1995;7:3-5.

Matched MeSH terms: Prostatic Hyperplasia

Benign prostatic hyperplasia: Shared care

Lei CCM

Family Physician, 1995;7:22-23.

Matched MeSH terms: Prostatic Hyperplasia

Fulltext Predicting outcome of trial of voiding without catheter in acute urinary retention with intravesical prostatic protrusion

Syazarina Sharis O, Zulkifli MZ, Hamzaini AH

Malays J Med Sci, 2013 Jan;20(1):56-9.

PMID: 23785255 MyJurnal

Acute urinary retention (AUR) is one of the most serious complications of benign prostatic hypertrophy. This study was done to predict the outcome of trial of voiding without catheter (TWOC) in patients with AUR with intravesical prostatic protrusion (IPP) detected on transabdominal ultrasound. Other factors such as prostatic volume and patient's age were also assessed.

Matched MeSH terms: Prostatic Hyperplasia

Fulltext Awareness of prostatism among male patients in Teluk Intan Hospital

Zainal SB, Quek KF, Biswajit C

Med J Malaysia, 2005 Dec;60(5):540-7.

PMID: 16515103

To determine the relationship between socio-demography, knowledge and attitude regarding prostatism among male in-patients in Teluk Intan Hospital. Two hundred respondents were recruited. Questionnaires that consist of demographic data such as age, ethnicity and religion and some question that pertaining knowledge and awareness were used. The questions eliciting symptoms of prostatism were based on the International Prostate Symptom Score (IPSS). 76.0% of the respondents were symptomatic as they presented with prostatic symptoms. The prevalence of asymptomatic cases is higher (6.7%) among the adults whereas the percentage in elderly respondents is higher than the adults in moderate to severe cases (p < 0.001). Only 10% of respondents have heard about prostatism and mass media is ranked highest as the most preferred source of information regarding this matter with 66.7% preference. About 85.70% of respondents who had a severe score and 18.5% who had a moderate score were dissatisfied with their quality of life due to prostatic symptoms. This study provides a deeper understanding on the prevalence and severity of the prostatic symptoms and its association with the quality of life. It also illustrates low awareness, poor health seeking behaviour and poor knowledge pertaining to prostatism among the study population.

Matched MeSH terms: Prostatic Hyperplasia/epidemiology*

Fulltext A personal experience with the first 100 TURP at the Penang General Hospital

Yeoh N, Inbasegaran K

Med J Malaysia, 1989 Jun;44(2):129-33.

PMID: 2483248

Transurethral Resection of the Prostate (TURP) is now the preferred method for dealing with the obstructing prostate. This procedure was reintroduced to the Penang General Hospital in August 1985. Over the next one and a half years, 100 TURP were performed by the author (NYTL). This paper reviews this initial experience. Of the patients, 17.7% required blood transfusion of one unit each. The mean post operative stay was 4.8 days. There were no immediate deaths. This experience confirms the acceptable results of TURP in the treatment of patients with benign prostatic hypertrophy in the Malaysian context.

Matched MeSH terms: Prostatic Hyperplasia/surgery*

MANAGEMENT OF PROSTATIC OBSTRUCTION IN THE ELDERLY MALE

MENON KA

Med J Malaysia, 1963 Dec;18:91-4.

PMID: 14117287

Matched MeSH terms: Prostatic Hyperplasia*

Fulltext The authors reply: Urethral strictures after bipolar transurethral resection of prostate may be linked to slow resection rate

Tan GH

Investig Clin Urol, 2018 01;59(1):68.

PMID: 29333519 DOI: 10.4111/icu.2018.59.1.68

Matched MeSH terms: Prostatic Hyperplasia/surgery

The quality of life outcome following treatment for lower urinary tract symptoms

Quek KF, Low WY, Razack AH, Loh CS, Chua CB

Asia Pac J Public Health, 2000;12(2):107-17.

PMID: 11836919 DOI: 10.1177/101053950001200210

This study aims to assess the impact of medical and surgical treatment on treating lower urinary tract symptoms (LUTS) on pain, prostatic symptoms, disease-specific quality of life and health-related quality of life. Patients scheduled for medical (alpha-blockers) and surgical treatment (transurethral resection of the prostate, TURP) were recruited in the study. The patients were assessed using the Visual Analogue Scale (VAS), Present Pain Intensity (PPI), International Prostate Symptom Score (I-PSS) and Health-Related Quality of Life (HRQOL) at 3-month, 6-month and 12-month (baseline). Before treatment, most of the patients with LUTS had severe pain, LUTS and deterioration of health-related quality of life. Following treatment, both medical and surgical treatment improved their pain, LUTS and health-related quality of life. Both treatments are effective in relieving the symptoms of pain, LUTS and health-related quality of life.

Matched MeSH terms: Prostatic Hyperplasia/complications*; Prostatic Hyperplasia/drug therapy; Prostatic Hyperplasia/surgery

Fulltext Cystic adenocarcinoma of prostate: a case report

Ng, K.L., Sathiyananthan, J.R., Dublin, N., Razack, A.H., Lee, G.

JUMMEC, 2011;14(1):21-22.

MyJurnal

Prostate cancer is not uncommon amongst the elderly men. Diagnosis is made using histopathology specimens of Transrectal Ultrasound guided biopsy of the prostate gland. However, prostate cancer presenting as a intra-prostatic cysts are rare. We report a case of elderly gentleman who presented with malignant intra-prostatic cysts.

Matched MeSH terms: Prostatic Hyperplasia

Urinary bladder characteristics via ultrasound as predictors of acute urinary retention in men with benign prostatic hyperplasia

Ho CC, Ngoo KS, Hamzaini AH, Rizal AM, Zulkifli MZ

Clin Ter, 2014;165(2):75-81.

PMID: 24770808 DOI: 10.7471/CT.2014.1680

OBJECTIVE: To determine the clinical utility of urinary bladder and prostate characteristics measured by ultrasound scan in predicting acute urinary retention (AUR) for men with bladder outlet obstruction with an underlying benign prostate hyperplasia (BPH).
MATERIALS AND METHODS: Consecutive men aged ≥50 years presenting with lower urinary tract symptoms (LUTS) or AUR were prospectively recruited in this cross-sectional study. International prostatic symptom score (IPSS) and serum prostate-specific antigen (PSA) were recorded. High-resolution ultrasound was used to measure bladder detrusor thickness (DT, mm), prostatic volume (PV, cm3), intravesical prostatic protrusion (IPP, mm), bladder wall thickness (BWT,mm), intravesical volume and bladder radius. The latter two parameters were used to estimate bladder weight (UEBW, g), assuming a spherical bladder.
RESULTS: Among selected patients, thirty had AUR while 32 men presented with LUTS only. There were significant differences between those with and without AUR in their age (70.5 vs 66.0, p=0.017), IPSS (24.0 vs 18.5, p=0.009), serum PSA (6.18 vs 1.77, p=0.002), PV (56.7 vs 32.4, p=0.006), BWT (5.0 vs 4.4, p=0.034) and UEBW (39.1 vs 25.0, p=0.0003). Multivariate analysis revealed high IPSS and UEBW to be predictors for AUR. UEBW was the strongest predictor of AUR: area under ROC curve was 0.767, with sensitivity and specificity of 63.3% and 87.5%, respectively, at cut-off point of 35 g. The likelihood ratio for AUR was also best with UEBW≥35 g.
CONCLUSIONS: Combined with IPSS, ultrasound determined bladder characteristic, particularly UEBW, is a useful tool in predicting AUR in men with BPH.

Matched MeSH terms: Prostatic Hyperplasia/complications*; Prostatic Hyperplasia/ultrasonography*

Reliability and validity of the Malay version of the International Prostate Symptom Score in the Malaysian population

Quek KF, Low WY, Razack AH, Sin Loh C, Chua CB

J Urol, 2002 Mar;167(3):1359-62.

PMID: 11832732

PURPOSE: We validated the Malay version of the International Prostate Symptom Score in patients with and without urinary symptoms in the Malaysian population.

MATERIALS AND METHODS: Validity and reliability were studied in patients with and without lower urinary tract symptoms. Reliability was evaluated using the test-retest method and internal consistency was assessed by Cronbach's alpha. Sensitivity to change was expressed as the effect size in the pre-intervention versus post-intervention score in additional patients with lower urinary tract symptoms who underwent transurethral prostate resection.

RESULTS: Internal consistency was excellent. A high degree of internal consistency was observed for each of the 7 items and for the total score (Cronbach's alpha 0.53 and greater, and 0.68, respectively). The test-retest correlation coefficients of the 7 items were highly significant. The intraclass correlation coefficient was high at 0.51 and greater. There was a high degree of sensitivity and specificity to the effects of treatment. Significant change from baseline to posttreatment scores was observed in all 8 items in the treated but not in the control group.

CONCLUSIONS: The Malay International Prostate Symptom Score is a suitable, reliable, valid instrument that is sensitive to clinical change in the Malaysian population.

Matched MeSH terms: Prostatic Hyperplasia/diagnosis*; Prostatic Hyperplasia/ethnology*

Fulltext Prevalence of symptomatic BPE among Malaysian men aged 50 and above attending screening during prostate health awareness campaign

Teh GC, Sahabudin RM, Lim TC, Chong WL, Woo S, Mohan M, et al.

Med J Malaysia, 2001 Jun;56(2):186-95.

PMID: 11771079

Objective: To study the prevalence of symptomatic BPE among Malaysian men age 50 and above attending prostate health awareness campaign and to identify differences in prevalence between different ethnic groups residing within metropolitan Kuala Lumpur.
Materials and Methods: Demographic data and the completed International Prostate Symptom Score (IPSS), maximal uroflow rate (Qmax) and prostate size of volunteers, aged 50 and above, who attended the prostate health awareness campaign were analyzed. Subjects with known prostate diseases or prostate surgery, bladder disorders and neurological disorders were excluded.
Results: 2086 volunteers attended the campaign. 575 men fulfilled the inclusion criteria and their demographic data, IPSS; peak flow rate and prostate volume were analysed. Overall, 18.9% and 39.6% of the men were severely and moderately symptomatic, respectively. The prevalence of moderate to severe lower urinary tract symptoms (LUTS) in Malays, Chinese and Indians were 70%, 59% and 50% respectively (p=0.004). The commonest bothersome symptoms were nocturia (56%), frequency (50.4%) and sense of incomplete voiding (43.5%). The mean peak flow rate of the subjects was 15.4ml/s. 20.9% and 55.2% of the subjects had peak flow less than 10ml/sec and 15ml/sec respectively. The mean prostate size was 25.1cc. There is no significant difference in term of maximal flow rate and prostate size among Malays, Chinese and Indians in Malaysia. A good correlation was found between the total symptom score and the single disease-specific quality of life question (r=0.69, p<0.001). The correlation between IPSS and peak flow rate (r=-0.22, p<0.001) and prostate volume (r=0.11, p=0.009) was weak. There was no correlation between IPSS and age (r=0.06, p=0.17). The prevalence of symptomatic benign prostate enlargement (BPE) was 39.3%. The prevalence increased 8% per decade from 41.7% for men aged 50 to 59 to 65.4% for men aged 70 or more. There is no significant difference in prevalence of symptomatic BPE among the three ethnic groups. The prevalence of BPO was 15.8%.
Conclusion: The correlation between symptom score, maximal flow rate and prostate size was poor and one cannot predict the value of one parameter by knowing one or more of the other parameters. There is a high prevalence of LUTS suggestive of benign prostatic obstruction in the apparently healthy Malaysian aged 50 and above attending the prostate health awareness campaign.

Matched MeSH terms: Prostatic Hyperplasia/diagnosis*; Prostatic Hyperplasia/epidemiology*

A Novel Calculator for Estimating Prostate Volume in Daily Urology Services

Lim J, Rampal S, Razack AHA, Malek R, Sundram M, Nasuha NA, et al.

Urology, 2018 Aug;118:145-151.

PMID: 29746873 DOI: 10.1016/j.urology.2018.02.055

OBJECTIVES: To develop a simple prostate volume (PV) calculator that can aid in managing patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement at daily urology services in developing Asian countries.

MATERIALS AND METHODS: We conducted a cross-sectional study of men aged above 40 years with no history of prostate cancer, prostate surgery, or 5α-reductase inhibitor treatment. Serum prostate-specific antigen (PSA) and total PV were measured in each subject. Potential sociodemographic and clinical variables including age, weight, comorbidities, and International Prostate Symptom Score (IPSS) were collected. Of 1034 subjects, 837 were used in building the PV calculator using regression analysis. The remaining 1/5 (n = 197) was used for model validation.

RESULTS: There were 1034 multiethnic Asian men (Chinese 52.9%, Malay 35.4%, and Indian 11.7%) with mean age of 60 ± 7.6 years. Average PV was 29.4 ± 13.0 mL while the overall mean of PSA was 1.7 ± 1.7 ng/mL. We identified age, IPSS, weight, and PSA (all P

Matched MeSH terms: Prostatic Hyperplasia/complications; Prostatic Hyperplasia/pathology*

Displaying publications 1 - 20 of 51 in total